| Literature DB >> 33161195 |
Yaoguang Zhou1, Zhuoer Sun1, Yan Wang1, Chenqi Xing1, Luna Sun1, Zhilei Shang1, Weizhi Liu2.
Abstract
BACKGROUND: Since the beginning of 21st century, several major public health emergencies (PHEs) have threatened the health of people globally. Posttraumatic stress symptoms (PTSS) was one of the most concerned mental health problems. The objective of this study is to systematically estimate the prevalence of PTSS under the influence of PHEs.Entities:
Keywords: Meta-analysis; Posttraumatic stress symptoms; Public health emergency; Systematic review
Year: 2020 PMID: 33161195 PMCID: PMC7588321 DOI: 10.1016/j.cpr.2020.101938
Source DB: PubMed Journal: Clin Psychol Rev ISSN: 0272-7358
Fig. 1PRISMA Flowchart of Study Selection.
Study characteristics of the included studies.
| Author(s) year | Country | epidemic | Time after | participants | Screening tool | Cutoffs | Valid sample size | Cases above cutoffs | prevalence | Quality rating |
|---|---|---|---|---|---|---|---|---|---|---|
| Singapore | SARS | 2 | HCWs | IES | 30 | 661 | 127 | 0.19 | 7 | |
| Canada | SARS | 0 | persons in quarantine | IES-R | 20 | 129 | 35 | 0.27 | 5 | |
| Singapore | SARS | 0 | medical stuff | IES-R | DMS-IV criteria | 277 | 26 | 0.09 | 7 | |
| Singapore | SARS | 6 | HCWs | IES | 26 | 96 | 17 | 0.18 | 7 | |
| China | SARS | 10 | patients | NR | NR | 29 | 1 | 0.03 | 6 | |
| China | SARS | 6 | residents | IES | NR | 818 | 128 | 0.16 | 5 | |
| China | SARS | 1 | patients | IES-R | 2(mean) | 195 | 11 | 0.06 | 8 | |
| China | SARS | 3 | patients | IES-R | 20 | 117 | 65 | 0.56 | 7 | |
| China | SARS | 6 | patients, HCWs, college students | PCL | NR | 162 | 9 | 0.06 | 7 | |
| China | SARS | 3 | patients | CIDI2.1 | NR | 286 | 28 | 0.10 | 7 | |
| China | SARS | 3 | patients, HCWs, community sample | IES-R | 20 | 296 | 115 | 0.39 | 7 | |
| Singapore | SARS | 3 | patients | IES | 26 | 63 | 26 | 0.41 | 7 | |
| China | SARS | 2 | residents | IES-R | 26 | 146 | 13 | 0.09 | 7 | |
| Canada | SARS | 19 | HCWs | IES | 26 | 769 | 96 | 0.12 | 7 | |
| China | SARS | 3 | patients | PTSD-SS + CCMDIII criteria | 48 | 67 | 31 | 0.46 | 8 | |
| 12 | 67 | 26 | 0.39 | |||||||
| ≥12 | 67 | 37 | 0.55 | |||||||
| China | SARS | 1.5 | HCWs | DTS-C | 40 | 83 | 16 | 0.19 | 7 | |
| China | SARS | 0 | nurses | DTS-C | 23 | 102 | 29 | 0.28 | 7 | |
| China | SARS | 12 | HCWs | CCMDIII criteria | – | 112 | 5 | 0.04 | 7 | |
| Canada | SARS | 19 | HCWs | CAPS | – | 139 | 2 | 0.01 | 7 | |
| Canada | SARS | 1 | persons in quarantine | IES-R | 20 | 1057 | 148 | 0.14 | 8 | |
| China | SARS | 2.5 | patients | IES + CCMDIII criteria | NR | 70 | 28 | 0.40 | 8 | |
| 7 | 61 | 25 | 0.41 | |||||||
| 10 | 57 | 22 | 0.39 | |||||||
| 24 | 58 | 23 | 0.40 | |||||||
| 46 | 57 | 24 | 0.39 | |||||||
| China | SARS | 30 | patients | IES-R | 2(mean) | 90 | 23 | 0.26 | 8 | |
| China | SARS | 36 | hospital employees | IES-R | 20 | 549 | 55 | 0.10 | 9 | |
| Singapore | SARS | 2 | persons visiting the community primary health care | IES-R | DMS-IV criteria | 415 | 107 | 0.26 | 7 | |
| Turkey | Crimean-Congo hemorrhagic fever | 12 | patients | DSM-IV-TR criteria | – | 54 | 10 | 0.19 | 7 | |
| Sierra Leone | Ebola | 0 | general public | PSS-I | NR | 1008 | 114 | 0.11 | 10 | |
| Guinea | Ebola | 0 | patients in psychiatric department | NR | NR | 68 | 4 | 0.04 | 7 | |
| Guinea | Ebola | 24 | patients with depressed symptom | NR | NR | 33 | 3 | 0.09 | 5 | |
| Sierra Leone | Ebola | 0 | aid workers | PDS-5 | 30 | 403 | 163 | 0.40 | 7 | |
| Sierra Leone | Ebola | 0 | general public | IES-6 | 9 | 3564 | 570 | 0.16 | 9 | |
| Korea | MERS | 0 | hospital workers | IES-R | 26 | 359 | 183 | 0.51 | 7 | |
| Liberia | Ebola | 0 | active duty soldiers,medical mission | PCL-S | 50 and DSM-IV criteria | 173 | 7 | 0.04 | 8 | |
| Korea | MERS | 12 | survivors | IES-R | 25 | 52 | 22 | 0.42 | 6 | |
| 18 | 52 | 14 | 0.27 | |||||||
| China | COVID-19 | 0 | HCWs | PTSD-SS | 50 | 230 | 63 | 0.27 | 8 | |
| Korea | MERS | 2 | nurses | IER-R | 25 | 147 | 37 | 0.25 | 7 | |
| China | COVID-19 | 0 | residents(hardest-hit) | PCL-5 | DSM-5 criteria | 285 | 20 | 0.07 | 8 | |
| China | COVID-19 | 0 | residents | PCL-5 | 33 | 2091 | 96 | 0.05 | 8 | |
| China | COVID-19 | 0 | nurses | PCL-C | 38 | 205 | 104 | 0.51 | 8 | |
| China | COVID-19 | 0 | villager | PTSD-SS | 50 | 87 | 2 | 0.02 | 7 | |
| China | COVID-19 | 0 | patients | PCL-5 | DSM-5 criteria | 190 | 43 | 0.23 | 8 |
a. These two studies used different screening tools for the same participants. The mean value of the results was obtained when analyzing overall estimated pooled prevalence.
Fig. 2Estimated prevalence of PTSS during or after PHE.
Note. Estimated prevalence = 0.170 (95% CI: 0.135–0.212).
Raw comparison between NES of prevalence of PTSD and the PTSS prevalence in the current study.
| National Epidemiologic Surveya | Current study | ||
|---|---|---|---|
| Partial PTSD | Full PTSD | PTSS | |
| 34,653 | 15,538 | ||
| Prevalence rate | 0.066 | 0.064 | 0.170 |
| Lower limit(95%CI) | 0.031 | 0.029 | 0.135 |
| Upper limit(95%CI) | 0.101 | 0.099 | 0.212 |
a. NES refers to an up-to-date assessment of the lifetime prevalence and Axis I comorbidity of DSM-IV PTSD and partial PTSD, with a representative sample of the civilian, noninstitutionalized U.S. population.
Estimated PTSS prevalence on different variables.
| k | n | Estimated rate | Lower limit | upper limit | Q-value | p for | |
|---|---|---|---|---|---|---|---|
| Country | |||||||
| Canada | 4 | 1955 | 0.124 | 0.070 | 0.212 | 27.574 | <0.001 |
| China | 21 | 6210 | 0.162 | 0.107 | 0.238 | 700.040 | <0.001 |
| Guinea | 2 | 101 | 0.063 | 0.029 | 0.134 | 0.836 | 0.361 |
| Korea | 3 | 558 | 0.365 | 0.206 | 0.560 | 28.333 | <0.001 |
| Liberia | 1 | 173 | 0.040 | 0.019 | 0.082 | 0.000 | 1.000 |
| Sierra Leone | 3 | 4975 | 0.203 | 0.100 | 0.336 | 163.101 | <0.001 |
| Singapore | 5 | 1512 | 0.208 | 0.141 | 0.295 | 42.938 | <0.001 |
| Turkey | 1 | 54 | 0.185 | 0.103 | 0.311 | 0.000 | 1.000 |
| Between group | 31.931 | <0.001 | |||||
| China vs other countries | |||||||
| China | 21 | 6210 | 0.162 | 0.107 | 0.232 | 496.261 | <0.001 |
| Other countries | 19 | 9328 | 0.178 | 0.134 | 0.238 | 700.040 | <0.001 |
| Between group | 0.148 | 0.070 | |||||
| Epidemic | |||||||
| COVID-19 | 6 | 3088 | 0.135 | 0.046 | 0.331 | 370.286 | <0.001 |
| Crimean-Congo hemorrhagic fever | 1 | 54 | 0.185 | 0.103 | 0.311 | 0.000 | 1.000 |
| Ebola | 6 | 5294 | 0.121 | 0.067 | 0.210 | 188.901 | <0.001 |
| MERS | 3 | 558 | 0.365 | 0.206 | 0.560 | 28.833 | <0.001 |
| SARS | 24 | 6589 | 0.174 | 0.134 | 0.223 | 403.181 | <0.001 |
| Between group | 7.921 | 0.095 | |||||
| SARS vs other PHEs | |||||||
| SARS | 24 | 6589 | 0.174 | 0.134 | 0.223 | 795.223 | <0.001 |
| Other PHEs | 16 | 8949 | 0.165 | 0.106 | 0.246 | 403.181 | <0.001 |
| Between group | 0.049 | 0.826 | |||||
| Time period (month) | |||||||
| 0 | 15 | 9171 | 0.161 | 0.103 | 0.242 | 809.485 | <0.001 |
| 1–3 | 13 | 3603 | 0.237 | 0.171 | 0.320 | 262.458 | <0.001 |
| 4–6 | 3 | 1076 | 0.124 | 0.071 | 0.207 | 11.068 | 0.004 |
| 7–12 | 6 | 432 | 0.256 | 0.141 | 0.419 | 38.503 | <0.001 |
| 13–24 | 6 | 1118 | 0.192 | 0.079 | 0.397 | 76.584 | <0.001 |
| >24 | 3 | 696 | 0.230 | 0.086 | 0.484 | 45.095 | <0.001 |
| Between group | 6.173 | 0.290 | |||||
| Population group | |||||||
| Community sample | 13 | 9791 | 0.124 | 0.091 | 0.166 | 266.269 | <0.001 |
| Healthcare workers | 16 | 4383 | 0.185 | 0.127 | 0.262 | 468.199 | <0.001 |
| <0.001 | |||||||
| <0.001 | |||||||
| patients | 14 | 1364 | 0.262 | 0.171 | 0.379 | 189.347 | <0.001 |
| Between group | 8.529 | 0.014 | |||||
| Screening method | |||||||
| Based on interview | 10 | 1886 | 0.108 | 0.063 | 0.181 | 92.905 | <0.001 |
| Based on self-report scale | 30 | 13,791 | 0.191 | 0.148 | 0.243 | 1085.232 | <0.001 |
| Between group | 3.693 | 0.051 | |||||
| Study quality | |||||||
| High | 3 | 5121 | 0.124 | 0.090 | 0.168 | 23.336 | <0.001 |
| Moderate | 34 | 9437 | 0.173 | 0.129 | 0.228 | 1045.855 | <0.001 |
| Low | 3 | 980 | 0.180 | 0.107 | 0.287 | 11.522 | 0.003 |
| Between group | 2.875 | 0.238 | |||||
Summary of meta-regression model using country, time, population group, screening method and study quality to explain variance across studies.
| Covariates included sequentially a | k | ΔTau2 | ΔR2 | Test of a single covariate within model | ||
|---|---|---|---|---|---|---|
| Q value | ||||||
| Country | 35 | −0.2317 | 0.25 | 10.51 | 7 | 0.1614 |
| Time | −0.0781 | 0.09 | 4.93 | 5 | 0.4246 | |
| Population group | −0.1715 | 0.18 | 11.59 | 2 | 0.0035 | |
| Screening method | −0.0740 | 0.08 | 6.90 | 1 | 0.0086 | |
| Study quality | −0.0338 | 0.04 | 3.43 | 2 | 0.1802 | |
| Tau2 | R2 | Test of the model | ||||
| The entire model | 0.3336 | 0.64 | 50.93 | 17 | <0.001 | |
a. The covariates were all included as dummy variables in the meta-regression model. Each had a reference group.
Fig. 3Funnel plot.
Note. Egger's Test of the Intercept shows intercept (B0) as-0.35502, with 95% confidence interval (−3.54659, 2.83655), t = 0.22519, df = 38. p = .41152.